Compares RNA-based NGS assays to evaluate actionable fusion detection in lung cancer, indicating sequencing strategy impacts diagnostic outcomes.
Key Points
To assess how different RNA-based next-generation sequencing technologies affect the detection of actionable gene fusions in non-small cell lung cancer.
Compared two RNA-based NGS assays: TruSight Oncology 500-RNA and Oncomine Focus Assay-RNA.
Analyzed RNA from 35 non-small cell lung cancer tumor samples.
Assessed fusion detection rates and identified discrepancies between the assays.
Identified 15 fusions in 13 of 35 tumors (37.2% detection rate).
TSO-500-RNA uniquely detected 13 fusions compared to 2 shared with OFA-RNA.
Overall detection rates: 9% for TSO-500-RNA and 6% for OFA-RNA.